LataMed AI is trading 11.26% higher at $0.09, following a broader healthcare-sector advance on September 25, 2026. - Healthcare stocks are benefiting from renewed biotechnology optimism, acquisition interest, and favorable regulatory expectations. - No fresh company-specific announcement was identified for September 25; the latest shareholder-update page concerns a July corporate action and does not explain the move. - Available evidence points mainly to sector-driven buying rather than a new LataMed AI catalyst.